May 8 |
Syndax Pharmaceuticals GAAP EPS of -$0.85 beats by $0.12
|
May 8 |
Syndax Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Clinical and Business Update
|
May 7 |
Syndax Pharmaceuticals Q1 2024 Earnings Preview
|
May 1 |
Syndax to Announce First Quarter 2024 Financial Results and Host Conference Call and Webcast on May 8, 2024
|
Apr 10 |
Syndax Announces Participation at the Stifel 2024 Virtual Targeted Oncology Forum
|
Apr 8 |
Syndax Presents Positive Pediatric Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia at ASPHO Plenary Session
|
Apr 5 |
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
|
Apr 3 |
Crinetics, Syndax gain amid pitch at Sohn charity conference (update)
|
Mar 28 |
Syndax (SNDX) Gets FDA Priority Tag for Leukemia Drug NDA
|
Mar 28 |
Syndax Pharmaceuticals: Upcoming Q3 PDUFAs Ignite Hope
|